Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

Acta dermato-venereologica·2026
Same author

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

The British journal of dermatology·2025
Same author

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

The British journal of dermatology·2025
Same author

Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale.

Journal of cutaneous pathology·2025
Same author

Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals.

Dermatology and therapy·2025
Same author

Understanding the Scalp: Dandruff and Seborrheic Dermatitis.

Journal of cutaneous medicine and surgery·2025
Same journal

'Cockade' or 'Targetoid' Variant of Syphilis.

Journal of cutaneous medicine and surgery·2026
Same journal

Tinea Imbricata.

Journal of cutaneous medicine and surgery·2026
Same journal

Intergenerational Clouston Syndrome.

Journal of cutaneous medicine and surgery·2026
Same journal

Herpes Zoster Ophthalmicus-Associated Trigeminal Trophic Syndrome.

Journal of cutaneous medicine and surgery·2026
Same journal

Borderline Lepromatous Leprosy Presenting Solely as a Nasal Plaque.

Journal of cutaneous medicine and surgery·2026
Same journal

Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice.

Journal of cutaneous medicine and surgery·2026
See all related articles

Related Experiment Videos

Update on alefacept safety.

Denise Wexler1, Gordon Searles, Ian Landells

  • 1Wellington Dermatology Association, London, ON. denisewexler@hotmail.com

Journal of Cutaneous Medicine and Surgery
|January 8, 2010
PubMed
Summary
This summary is machine-generated.

The AWARE study found alefacept to be a safe treatment for chronic plaque psoriasis in Canada. Real-world evidence supports its use alone or with other therapies, with minimal drug-related adverse events.

Related Experiment Videos

Area of Science:

  • Dermatology and Immunology

Background:

  • Alefacept is a proven effective and safe therapy for chronic plaque psoriasis.
  • It can be used as monotherapy or in combination with other antipsoriatic treatments.

Purpose of the Study:

  • To evaluate the real-world efficacy and safety of alefacept in Canadian patients with psoriasis.
  • The AWARE registry (Amevive Wisdom Acquired from Real-World Evidence) is a phase IV observational study.

Main Methods:

  • Patients with chronic plaque psoriasis received alefacept, followed by a treatment break of at least 12 weeks.
  • Prospective follow-up extended to at least 60 weeks, with safety data including serious adverse events (SAEs).

Main Results:

  • Only one of twelve reported SAEs was possibly related to alefacept.
  • Missed doses occurred in about 25% of patients, primarily due to low CD4(+) counts, but no permanent discontinuation was needed.
  • Treatment discontinuation was infrequent, with patient request being the most common reason.

Conclusions:

  • The AWARE study confirms the safety profile of alefacept in a diverse Canadian patient population with chronic plaque psoriasis.
  • Real-world data supports alefacept's use as a safe therapeutic option, alone or combined with other psoriasis treatments.